SubHero Banner

Keytruda® (pembrolizumab) – New indication

September 22, 2017 – Merck announced the FDA approval of Keytruda (pembrolizumab) injection, for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ≥ 1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy.

Download PDF